ZLAB Zai Lab Ltd. Sponsored ADR

Zai Lab Announces Upcoming Presentations in June Investor Conferences

Zai Lab Announces Upcoming Presentations in June Investor Conferences

SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in June:

Jefferies Healthcare Conference 2021

Presentation: Wednesday, June 2, 2021 at 10:00 a.m. EDT

J.P. Morgan Global China Summit

Panel Discussion: Thursday, June 3, 2021 at 10:45 a.m. HKT

Goldman Sachs 42nd Annual Global Healthcare Conference

Fireside Chat: Tuesday, June 8, 2021 at 8:50 a.m. EDT

Live webcasts of the conferences will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit or follow us at /ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab

Billy Cho, CFO

01

Media: Ryo Imai / Robert Flamm, Ph.D.

Burns McClellan, on behalf of Zai Lab

212-213-0006 ext. 315 / 364

/

Investors: Pete Rahmer / Mike Zanoni

Endurance Advisors, on behalf of Zai Lab

415-515-9763 / 610-442-8570

/

Zai Lab Limited

Source: Zai Lab Limited



EN
25/05/2021

Underlying

ZLABZai Lab Ltd. Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zai Lab Ltd. Sponsored ADR

Free Trial
ZLAB Zai Lab Ltd. Sp...

Zai Lab Limited: 1 director

A director at Zai Lab Limited sold 9,618 shares at 30.000USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

ZLAB ZAI LAB LTD. SPONSORED ADR
06/04/25 June 4, 2025 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER)VYVGART® (efgartigimod alfa injection) achieved $4.9 million sales since its commercial launch in September in ChinaStrong balance sheet with a cash position of $822.2 million as of September 30, 2023, compared to $876.4 million as of June 30, 2023Company to host conference call and webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mas...

November 7, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Announces Participation in November Investor Conferences SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023: Jefferies London Healthcare ConferenceFireside Chat: Wednesday, November 15th at 1:00 p.m. GMTLocation: London 6th Annual Evercore ISI HealthCONx ConferenceFireside Chat: Wednesday, November 29th at 1:45 p.m. ESTLocation: Miami A live webcast of the presentations will b...

October 26, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Co...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on November 7, 2023. The Company will host a live conference call and webcast on November 8, 2023, at 8:00 a.m. ET. Conference Ca...

October 18, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinatin...

September 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch